Smruthi Organics Ltd
BBSE:SMRUTHIORG133.50
INR
-1.95
(-1.44%)
ISIN
INE172E01011
Return %
Stock
S&P 500
1Y
0.07
14.39
3Y
-20.70
81.42
5Y
-52.17
68.62
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Purushotham Malaiah Eaga
- Full Time Employees
- 261
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 165-A, Balaji Bhavan Solapur MA India 413001
- IPO Date
- Aug 29, 2017
- Website
- smruthiorganics.com
- Similar Companies
- Business
- Smruthi Organics Limited manufactures and markets active pharmaceutical ingredients (APIs) primarily in the therapeutic categories of anti-diabetic, anti-hypertension, and anti-infectives. Its product portfolio includes cardiovascular APIs such as amlodipine besilate, losartan potassium, telmisartan, s-amlodipine besilate, s-amlodipine malelate, and valsartan; anti-diabetic APIs including metformin HCL, vildagliptin, teneligliptin, and dapagliflozin; anti-infective APIs like ciprofloxacin HCL, diloxanide furoate, norfloxacin, and pefloxacin mesylate; and anti-platelet products such as ticagrelor. The company also develops key drug intermediates, including amlodipine base variants and bulk drugs. It serves both the Indian domestic market and international markets across Asia, the Americas, and Africa from its headquarters in Solapur, Maharashtra, India. Smruthi Organics operates a GMP WHO-approved manufacturing facility certified by India’s CDSCO, ensuring compliance with global quality standards. In the last 1-2 years, Smruthi Organics has focused strategically on backward integration and expansion into finished dosage forms (FDF) manufacturing, aiming to enhance its product offerings and increase presence in PIC/S signatory countries, which reflects efforts to expand its global footprint. Additionally, the company acquired manufacturing licenses for APIs hydroxychloroquine and chloroquine sulphate, expanding its portfolio in anti-infective therapy. Recent quarters reflect a strengthened revenue performance, supported by new client acquisitions and partnerships with global system integrators, signaling enhanced market traction and operational scale. Smruthi Organics continues its commitment to technology innovation through active research and development, delivering new molecules and process improvements for future commercial scalability. Founded in 1989, the company remains independently listed on Indian stock exchanges under ticker SMRUTHIORG.BO. It maintains a customer base comprising large domestic and international pharmaceutical companies, with a high concentration of sales from its top products metformin and telmisartan. Smruthi Organics’ business model integrates API manufacturing, drug intermediate production, and an emerging focus on finished dosage forms, targeting pharmaceutical manufacturers requiring reliable, high-quality ingredient supply supported by regulatory compliance and global distribution capabilities.